Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychedelics and Psychedelic-Assisted Psychotherapy
Collin Reiff, Elon E. Richman, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2020) Vol. 177, Iss. 5, pp. 391-410
Closed Access | Times Cited: 451

Showing 26-50 of 451 citing articles:

Registered clinical studies investigating psychedelic drugs for psychiatric disorders
Ashley Siegel, Shakila Meshkat, Katie Benitah, et al.
Journal of Psychiatric Research (2021) Vol. 139, pp. 71-81
Closed Access | Times Cited: 69
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Rita Kočárová, Jiřı́ Horáček, Robin Carhart‐Harris
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 65
Novel drug developmental strategies for treatment‐resistant depression
Éva Borbély, Mária Simon, Eberhard Fuchs, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 6, pp. 1146-1186
Open Access | Times Cited: 65
Risks and Benefits of Cannabis and Cannabinoids in Psychiatry
Kevin P. Hill, Mark S. Gold, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2021) Vol. 179, Iss. 2, pp. 98-109
Closed Access | Times Cited: 65
Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice
Yuria Celidwen, Nicole Redvers, Cicilia Githaiga, et al.
The Lancet Regional Health - Americas (2022) Vol. 18, pp. 100410-100410
Open Access | Times Cited: 62
The therapeutic potential of psilocybin: a systematic review
Jan van Amsterdam, Wim van den Brink
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 833-840
Closed Access | Times Cited: 58
Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment
Johannes Thrul, Albert Garcia‐Romeu
Drugs Education Prevention and Policy (2021) Vol. 28, Iss. 3, pp. 211-214
Open Access | Times Cited: 57
Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers
Jerome Sarris, Daniel Perkins, Lachlan Cribb, et al.
Journal of Affective Disorders Reports (2021) Vol. 4, pp. 100098-100098
Open Access | Times Cited: 55
The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics
Aviad Hadar, Jonathan David, Nadav Shalit, et al.
Journal of Psychoactive Drugs (2022) Vol. 55, Iss. 1, pp. 1-10
Closed Access | Times Cited: 54
The Rapid Rise in Investment in Psychedelics—Cart Before the Horse
Joshua Phelps, Ravi N. Shah, Jeffrey A. Lieberman
JAMA Psychiatry (2022) Vol. 79, Iss. 3, pp. 189-189
Closed Access | Times Cited: 53
The challenges ahead for psychedelic ‘medicine’
Suresh Muthukumaraswamy, Anna Forsyth, Rachael L. Sumner
Australian & New Zealand Journal of Psychiatry (2022) Vol. 56, Iss. 11, pp. 1378-1383
Closed Access | Times Cited: 48
Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model
Bill Brennan, Alexander B. Belser
Frontiers in Psychology (2022) Vol. 13
Open Access | Times Cited: 48
The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision
Darron T. Smith, Sonya C. Faber, NiCole T. Buchanan, et al.
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 43
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
Guang Chen, Li Chen, Yun Zhang, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 4, pp. 269-279
Open Access | Times Cited: 42
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability
Gregory Barber, Charles B. Nemeroff, Steven Siegel
American Journal of Psychiatry (2022) Vol. 179, Iss. 12, pp. 892-896
Closed Access | Times Cited: 42
Novel ethical and policy issues in psychiatric uses of psychedelic substances
William Smith, Paul S. Appelbaum
Neuropharmacology (2022) Vol. 216, pp. 109165-109165
Open Access | Times Cited: 40
Acute psilocybin enhances cognitive flexibility in rats
Alejandro Torrado Pacheco, Randall J. Olson, Gabriela Garza, et al.
Neuropsychopharmacology (2023) Vol. 48, Iss. 7, pp. 1011-1020
Open Access | Times Cited: 39
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder
Joshua D. Rosenblat, M. Ishrat Husain, Yena Lee, et al.
The Canadian Journal of Psychiatry (2022) Vol. 68, Iss. 1, pp. 5-21
Open Access | Times Cited: 38
Pattern breaking: a complex systems approach to psychedelic medicine
Inês Hipólito, Jonas Mago, Fernando E. Rosas, et al.
Neuroscience of Consciousness (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 38
Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder
Nicolas Singewald, Simone B. Sartori, Andreas Reif, et al.
Neuropharmacology (2023) Vol. 226, pp. 109418-109418
Open Access | Times Cited: 37
Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry
Gregory Barber, Charles C. Dike
Psychiatric Services (2023) Vol. 74, Iss. 8, pp. 838-846
Closed Access | Times Cited: 37
Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study
Natasha L. Mason, Attila Szabó, Kim P. C. Kuypers, et al.
Brain Behavior and Immunity (2023) Vol. 114, pp. 299-310
Open Access | Times Cited: 37
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects
Joshua D. Rosenblat, Marisa Leon-Carlyle, Shaun Ali, et al.
American Journal of Psychiatry (2023) Vol. 180, Iss. 5, pp. 395-396
Closed Access | Times Cited: 30
Therapeutic mechanisms of psychedelics and entactogens
Boris D. Heifets, David E. Olson
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 104-118
Closed Access | Times Cited: 29

Scroll to top